Cladribine

Originally an anti-cancer chemotherapy drug used in the treatment of leukaemia. The injectable form of Cladribine has been trialled for MS but this did not show any change in relapse rate or any slowing of progression.

However, now there are trials underway of an oral form of Cladribine for relapsing/remitting MS and it seems that this drug may be able to reduce the number of lesions, reduce relapse rates and slow disability progression.

Cladribine is used to kill off cells in the immune system, similar to that of Alemtuzumab (campath). During trial reported side-effects included bone marrow suppression with reduced platelet count, fatigue, nausea, rash, headache and reduction of appetite. It also increase the risk of infection to some viruses.

Approved Use

Cladribine is not yet approved and is still undergoing trials.

Side Effects

It appears that Cladribine has an extensive list of possible side-effects which can include:

  • Bruising and Bleeding
  • Anaemia
  • Build up of fluid
  • Skin Changes
  • Nausea
  • Tireness
  • Loss of Appetite

References

Cladribine – Macmillan Cancer Support

Cladribine on Wikipedia

Cladribine an anti cancer drug that may reduce lesions and relapse in MS
Tagged on:             

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close